Aspen Pharmacare shrugged off Thursday’s broad market slump after receiving unsolicited offers for parts of its business, with Naspers and Prosus leading the JSE sharply lower amid another regulatory crackdown on China’s technology sector.

Aspen, SA’s largest pharmaceutical company by market capitalisation, rose the most in four months on Thursday after saying it had received two offers to buy parts of its global active pharmaceutical ingredients (API), which manufacturers the active ingredients used in medications...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.